Yesterday, the US Senate unanimously approved the FDA Modernization Act 2.0,
which was previously approved by the Lower House. This new bill which is expected to become a law soon aims to reduce testing with mammals, becoming a change accelerator for NemaLife, and increasing adoption of our cruelty-free platform.
This bill allows an applicant for market approval for a new drug to use methods other than animal testing to establish the drug's safety and effectiveness. Under this bill, these alternative methods may include cell-based assays, organ chips and microphysiological systems, sophisticated computer modeling, and other human biology-based test methods.
We invite companies in the foodtech, pharma, nutraceuticals, and microbiome space to reach out to us on how to obtain non-mammalian in vivo data and prepare for these changes in the regulatory landscape.